Markets Canaccord ups Neuronetics PT to $20 from $8 Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared... January 19, 2021